NCT04265872 2026-02-12
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
Clinical Trials
6 trialsNCT06637306 2025-03-26
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT02872025 2025-01-30
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
University of California, San Francisco
Phase EARLY_PHASE1 Active not recruiting
NCT03514121 2024-11-22
FPA150-001
Five Prime Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT03197389 2021-05-19
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Completed